TG Therapeutics reports positive Phase 1 data for subcutaneous BRIUMVI; bioavailability >60% vs IV

TG THERAPEUTICS, INC.

Mean bioavailability >60% relative to IV; lower bound of 95% CI >55%.
PK modeling predicts non-inferior total drug exposure for quarterly SC dosing (GMR 1.21, lower 90% CI 1.15).
Subcutaneous BRIUMVI well tolerated; injection-site reactions <5%, no new safety signals.
B-cell depletion with SC consistent with IV; supports biologic activity.
Phase 3 fully enrolled; top-line data expected late 2026 or early 2027; potential approval in 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.